{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:58:47Z","timestamp":1786985927615,"version":"build-2736575974"},"reference-count":313,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T00:00:00Z","timestamp":1720310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Calcium"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ceca.2024.102928","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T12:08:45Z","timestamp":1720267725000},"page":"102928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Targeting calciumopathy for neuroprotection: focus on calcium channels Cav1, Orai1 and P2X7"],"prefix":"10.1016","volume":"123","author":[{"given":"Myriam","family":"Torres-Rico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Garc\u00eda-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Gironda-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Pascual-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio G.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5265-1361","authenticated-orcid":false,"given":"Victoria","family":"Maneu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ceca.2024.102928_bib0035","series-title":"Comprehensive Physiology","first-page":"1443","article-title":"Chromaffin cells of the adrenal medulla: physiology, pharmacology, and disease","author":"Carbone","year":"2019"},{"key":"10.1016\/j.ceca.2024.102928_bib0088","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1152\/physrev.00039.2005","article-title":"Calcium signaling and exocytosis in adrenal chromaffin cells","volume":"86","author":"Garc\u00eda","year":"2006","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ceca.2024.102928_bib0201","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0896-6273(00)80983-6","article-title":"Vesicle pools and Ca2+ microdomains: new tools for understanding their roles in neurotransmitter release","volume":"20","author":"Neher","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.ceca.2024.102928_bib0270","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1474-9726.2007.00299.x","article-title":"Role of calcium in normal aging and neurodegeneration","volume":"6","author":"Toescu","year":"2007","journal-title":"Aging Cell"},{"key":"10.1016\/j.ceca.2024.102928_bib0082","first-page":"563","article-title":"Myocardial fiber necrosis due to intracellular Ca overload-a new principle in cardiac pathophysiology","volume":"4","author":"Fleckenstein","year":"1974","journal-title":"Recent Adv Stud Card. Struct Metab"},{"key":"10.1016\/j.ceca.2024.102928_bib0156","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1083\/jcb.82.3.811","article-title":"Agonist-induced myopathy at the neuromuscular junction is mediated by calcium","volume":"82","author":"Leonard","year":"1979","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ceca.2024.102928_bib0244","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.386513","article-title":"Calcium dependence of toxic cell death: a final common pathway","volume":"206","author":"Schanne","year":"1979","journal-title":"Science (80-.)"},{"key":"10.1016\/j.ceca.2024.102928_bib0272","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1096\/fasebj.9.2.7781924","article-title":"Calcium-mediated cell injury and cell death","volume":"9","author":"Trump","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.ceca.2024.102928_bib0034","doi-asserted-by":"crossref","first-page":"39695","DOI":"10.1074\/jbc.M102334200","article-title":"Calcium entry through l-type calcium channels causes mitochondrial disruption and chromaffin cell death","volume":"276","author":"Cano-Abad","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ceca.2024.102928_bib0169","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/archopht.1957.00940010205006","article-title":"The toxic effect of sodium l-glutamate on the inner layers of the retina","volume":"58","author":"Lucas","year":"1957","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ceca.2024.102928_bib0048","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1523\/JNEUROSCI.07-02-00357.1987","article-title":"Glutamate neurotoxicity in cortical cell culture","volume":"7","author":"Choi","year":"1987","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0085","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1749-6632.1994.tb44410.x","article-title":"Elevated intracellular calcium blocks programmed neuronal death","volume":"747","author":"Franklin","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0086","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0166-2236(92)90103-F","article-title":"Suppression of programmed neuronal death by sustained elevation of cytoplasmic calcium","volume":"15","author":"Franklin","year":"1992","journal-title":"Trends. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0051","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-8993(89)90465-4","article-title":"The role of dihydropyridine-sensitive voltage-gated calcium channels in potassium-mediated neuronal survival","volume":"502","author":"Collins","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.ceca.2024.102928_bib0269","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/bj3570137","article-title":"Elevated extracellular [K+] inhibits death-receptor- and chemical-mediated apoptosis prior to caspase activation and cytochrome c release","volume":"357","author":"Thompson","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.ceca.2024.102928_bib0305","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0955-0674(00)00228-3","article-title":"Ion homeostasis and apoptosis","volume":"13","author":"Yu","year":"2001","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ceca.2024.102928_bib317","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1073\/pnas.88.9.3892","article-title":"Evidence that nerve growth factor dependence of sympathetic neurons for survival in vitro may be determined by levels of cytoplasmic free Ca2+","volume":"88","author":"Koike","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0209","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nrm1150","article-title":"Regulation of cell death: the calcium-apoptosis link","volume":"4","author":"Orrenius","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ceca.2024.102928_bib0005","doi-asserted-by":"crossref","unstructured":"Alexianu, M.E., Ho, B., Mohamed, A.H., La Bella, V. Smith, R.G., Appel, S.H., 1994. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann. Neurol. 36, 846\u2013858. https:\/\/doi.org\/10.1002\/ana.410360608.","DOI":"10.1002\/ana.410360608"},{"key":"10.1016\/j.ceca.2024.102928_bib0016","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1046\/j.1471-4159.2001.00582.x","article-title":"Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosis","volume":"79","author":"Beers","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ceca.2024.102928_bib0110","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1073\/pnas.93.13.6796","article-title":"Expression of calbindin-D28K in motoneuron hybrid cells after retroviral infection with calbindin-D28K cDNA prevents amyotrophic lateral sclerosis IgG-mediated cytotoxicity","volume":"93","author":"Ho","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0279","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1006\/exnr.2001.7858","article-title":"Protective effect of parvalbumin on excitotoxic motor neuron death","volume":"174","author":"Van Den Bosch","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ceca.2024.102928_bib0307","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.bbamem.2013.03.014","article-title":"Advances in voltage-gated calcium channel structure, function and physiology","volume":"1828","author":"Zamponi","year":"2013","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"key":"10.1016\/j.ceca.2024.102928_bib0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1124\/pr.57.4.5","article-title":"International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels","volume":"57","author":"Catterall","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ceca.2024.102928_bib0039","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/pr.57.4.4","article-title":"International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels","volume":"57","author":"Catterall","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ceca.2024.102928_bib0166","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1152\/jn.00486.2004","article-title":"l-type calcium channels: the low down","volume":"92","author":"Lipscombe","year":"2004","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.ceca.2024.102928_bib0013","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1126\/science.8097060","article-title":"Regulation of Gene Expression in Hippocampal Neurons by Distinct Calcium Signaling Pathways","volume":"260","author":"Bading","year":"1993","journal-title":"Science (80-.)"},{"key":"10.1016\/j.ceca.2024.102928_bib0089","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/309069a0","article-title":"Dihydropyridine BAY-K-8644 activates chromaffin cell calcium channels","volume":"309","author":"Garc\u00eda","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.ceca.2024.102928_bib0020","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/jnr.21930","article-title":"Nimodipine inhibits TMB-8 potentiation of AMPA-induced hippocampal neurodegeneration","volume":"87","author":"Bernal","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ceca.2024.102928_bib0316","first-page":"PL221","article-title":"Nimodipine inhibits calcium-independent nitric oxide synthase activity in transient focal cerebral ischemia rats and cultured mouse astroglial cells","volume":"65","author":"Zhu","year":"1999","journal-title":"Life Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0113","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/01.STR.32.2.461","article-title":"Very early nimodipine use in stroke (VENUS)","volume":"32","author":"Horn","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.ceca.2024.102928_bib0219","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0197-0186(03)00136-0","article-title":"Nimodipine and TMB-8 potentiate the AMPA-induced lesion in the basal ganglia","volume":"44","author":"Petegnief","year":"2004","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ceca.2024.102928_bib0227","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/0024-3205(94)00391-2","article-title":"Neuronal protective effects of calcium antagonists in cerebral ischemia","volume":"55","author":"Rami","year":"1994","journal-title":"Life Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0252","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0006-8993(96)01385-6","article-title":"Identification of calcium channels involved in neuronal injury in rat hippocampal slices subjected to oxygen and glucose deprivation","volume":"753","author":"Small","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.ceca.2024.102928_bib0205","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0014-2999(98)00916-9","article-title":"Effects of dotarizine and flunarizine on chromaffin cell viability and cytosolic Ca2+","volume":"366","author":"Novalbos","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0295","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1039\/C5MB00781J","article-title":"Binding mechanisms of 1,4-dihydropyridine derivatives to L-type calcium channel Ca v 1.2: a molecular modeling study","volume":"12","author":"Xu","year":"2016","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.ceca.2024.102928_bib0266","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1124\/mol.119.117531","article-title":"Structural basis for diltiazem block of a voltage-gated ca 2+ channel","volume":"96","author":"Tang","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109931","article-title":"Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2.2","volume":"37","author":"Dong","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ceca.2024.102928_bib0052","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0960-5428(95)00031-3","article-title":"Induction of nitric oxide in cultured microglia: evidence for a cytoprotective role","volume":"5","author":"Colton","year":"1995","journal-title":"Adv. Neuroimmunol."},{"key":"10.1016\/j.ceca.2024.102928_bib0076","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.mcn.2014.12.004","article-title":"The l-type voltage-gated calcium channel modulates microglial pro-inflammatory activity","volume":"64","author":"Espinosa-Parrilla","year":"2015","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0249","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0006-8993(98)01272-4","article-title":"Activation of microglial cells by PrP and \u03b2-amyloid fragments raises intracellular calcium through l-type voltage sensitive calcium channels","volume":"818","author":"Silei","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.ceca.2024.102928_bib0161","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.neuropharm.2008.10.016","article-title":"Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation","volume":"56","author":"Li","year":"2009","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.ceca.2024.102928_bib0274","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1471-4159.1997.68010265.x","article-title":"Amyloid \u03b2 protein potentiates Ca2+ influx through l-type voltage-sensitive Ca2+ channels: a possible involvement of free radicals","volume":"68","author":"Ueda","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ceca.2024.102928_bib0246","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1096\/fj.04-2659fje","article-title":"Alzheimer's amyloid peptides mediate hypoxic up-regulation of l-type Ca 2+ channels","volume":"19","author":"Scragg","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.ceca.2024.102928_bib0058","article-title":"Green-Fluorescent Protein+ Astrocytes Attach to Beta-Amyloid Plaques in an Alzheimer Mouse Model and Are Sensitive for","volume":"8","author":"Daschil","year":"2016","journal-title":"Clasmatodendrosis. Front. Aging Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0298","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bcp.2003.11.005","article-title":"Protective effects of a selective l-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death","volume":"67","author":"Yagami","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0009","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.nbd.2010.08.020","article-title":"L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease","volume":"41","author":"Anekonda","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ceca.2024.102928_bib0031","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1113\/JP277487","article-title":"Impaired chromaffin cell excitability and exocytosis in autistic Timothy syndrome TS2-neo mouse rescued by l-type calcium channel blockers","volume":"597","author":"Calorio","year":"2019","journal-title":"J. Physiol."},{"key":"10.1016\/j.ceca.2024.102928_bib0213","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2119\/molmed.2010.00180","article-title":"Selective antihypertensive dihydropyridines lower A\u03b2 accumulation by targeting both the production and the clearance of A\u03b2 across the blood-brain barrier","volume":"17","author":"Paris","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0210","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.162100","article-title":"The human channel gating\u2013modifying A749G CACNA1D (Cav1.3) variant induces a neurodevelopmental syndrome\u2013like phenotype in mice","volume":"8","author":"Ortner","year":"2023","journal-title":"JCI. Insight."},{"key":"10.1016\/j.ceca.2024.102928_bib0159","article-title":"Mechanism of neural regeneration induced by natural product LY01 in the 5\u00d7FAD mouse model of alzheimer's disease","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0300","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neurobiolaging.2004.03.009","article-title":"Calcium channel blockers and risk of AD: the baltimore longitudinal study of aging","volume":"26","author":"Yasar","year":"2005","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ceca.2024.102928_bib0104","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/gps.1851","article-title":"Nilvadipine prevents cognitive decline of patients with mild cognitive impairment","volume":"22","author":"Hanyu","year":"2007","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.ceca.2024.102928_bib0182","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/RLU.0b013e31815c4ff0","article-title":"Effect of nilvadipine on regional cerebral blood flow in a patient with early alzheimer disease","volume":"33","author":"Matsuda","year":"2008","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0083","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1001\/archinte.162.18.2046","article-title":"The prevention of dementia with antihypertensive treatment<subtitle>new evidence from the systolic hypertension in europe (syst-eur) study<\/subtitle>","volume":"162","author":"Forette","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0206","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/mds.27115","article-title":"Past, present, and future of Parkinson's disease: a special essay on the 200th Anniversary of the Shaking Palsy","volume":"32","author":"Obeso","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ceca.2024.102928_bib0149","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00001756-199503000-00009","article-title":"Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice","volume":"6","author":"Kupsch","year":"1995","journal-title":"Neuroreport"},{"key":"10.1016\/j.ceca.2024.102928_bib0251","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104897","article-title":"Potential anti-neuroinflammatory compounds from Australian plants \u2013 A review","volume":"142","author":"Singh","year":"2021","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ceca.2024.102928_bib0287","doi-asserted-by":"crossref","first-page":"47284","DOI":"10.18632\/oncotarget.17618","article-title":"Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ceca.2024.102928_bib0288","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12640-011-9271-x","article-title":"L-Type Cav1.2 calcium channel is involved in 6-hydroxydopamine-induced neurotoxicity in rats","volume":"21","author":"Wang","year":"2012","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.ceca.2024.102928_bib0015","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"70","author":"Becker","year":"2008","journal-title":"Neurology."},{"key":"10.1016\/j.ceca.2024.102928_bib0154","doi-asserted-by":"crossref","first-page":"e98961","DOI":"10.1371\/journal.pone.0098961","article-title":"Antihypertensive agents and risk of parkinson's disease: a nationwide cohort study","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS. One"},{"key":"10.1016\/j.ceca.2024.102928_bib0215","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/aje\/kwr362","article-title":"Use of calcium channel blockers and parkinson's disease","volume":"175","author":"Pasternak","year":"2012","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ceca.2024.102928_bib0232","article-title":"L-type calcium channel blockers and parkinson's disease in denmark","author":"Ritz","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ceca.2024.102928_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/697404","article-title":"Reduced risk of Parkinson's disease in users of calcium channel blockers: a meta-analysis","volume":"2015","author":"Gudala","year":"2015","journal-title":"Int. J. Chronic Dis."},{"key":"10.1016\/j.ceca.2024.102928_bib0152","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/pds.3781","article-title":"Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis","volume":"24","author":"Lang","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ceca.2024.102928_bib0196","first-page":"1","article-title":"Risk of parkinson's disease in the users of antihypertensive agents: an evidence from the meta-analysis of observational studies","author":"Mullapudi","year":"2016","journal-title":"J. Neurodegener. Dis."},{"key":"10.1016\/j.ceca.2024.102928_bib0220","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/mds.25639","article-title":"Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)","volume":"28","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ceca.2024.102928_bib0126","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/M19-2534","article-title":"Isradipine versus placebo in early parkinson disease","volume":"172","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0184","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3233\/JPD-189004","article-title":"Clinical trial highlights: targeting alpha-synuclein","volume":"9","author":"McFarthing","year":"2019","journal-title":"J. Parkinsons. Dis."},{"key":"10.1016\/j.ceca.2024.102928_bib0282","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/acn3.51300","article-title":"Isradipine plasma pharmacokinetics and exposure\u2013response in early Parkinson's disease","volume":"8","author":"Venuto","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ceca.2024.102928_bib0071","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/0166-2236(90)90111-M","article-title":"Excitotoxic injury of the neostriatum: a model for Huntington's disease","volume":"13","author":"DiFiglia","year":"1990","journal-title":"Trends. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0029","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/exnr.1999.7092","article-title":"Metabotropic Glutamate Receptors and Cell-Type-Specific Vulnerability in the Striatum: implication for Ischemia and Huntington's Disease","volume":"158","author":"Calabresi","year":"1999","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ceca.2024.102928_bib0228","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bbrc.2016.07.058","article-title":"Striatal synaptic dysfunction and altered calcium regulation in Huntington disease","volume":"483","author":"Raymond","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ceca.2024.102928_bib0190","doi-asserted-by":"crossref","DOI":"10.1177\/1759091419856811","article-title":"Alterations of calcium channels in a mouse model of huntington's disease and neuroprotection by blockage of Ca V 1 channels","volume":"11","author":"Miranda","year":"2019","journal-title":"ASN. Neuro"},{"key":"10.1016\/j.ceca.2024.102928_bib0226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0143-4160(86)90026-6","article-title":"A model for receptor-regulated calcium entry","volume":"7","author":"Putney","year":"1986","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ceca.2024.102928_bib0165","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.cub.2005.05.055","article-title":"STIM is a Ca2+ sensor essential for Ca2+-Store-depletion-triggered Ca2+ influx","volume":"15","author":"Liou","year":"2005","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ceca.2024.102928_bib0234","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1083\/jcb.200502019","article-title":"STIM1, an essential and conserved component of store-operated Ca2 + channel function","volume":"169","author":"Roos","year":"2005","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ceca.2024.102928_bib0283","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1127883","article-title":"CRACM1 is a plasma membrane protein essential for store-operated Ca 2+ entry","volume":"312","author":"Vig","year":"2006","journal-title":"Science (80-.)"},{"key":"10.1016\/j.ceca.2024.102928_bib0310","doi-asserted-by":"crossref","first-page":"9357","DOI":"10.1073\/pnas.0603161103","article-title":"Genome-wide RNAi screen of Ca 2+ influx identifies genes that regulate Ca 2+ release-activated Ca 2+ channel activity","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0223","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature05122","article-title":"Orai1 is an essential pore subunit of the CRAC channel","volume":"443","author":"Prakriya","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ceca.2024.102928_bib0187","doi-asserted-by":"crossref","first-page":"24979","DOI":"10.1074\/jbc.M604589200","article-title":"Large Store-operated calcium selective currents due to co-expression of orai1 or Orai2 with the intracellular calcium sensor, Stim1","volume":"281","author":"Mercer","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ceca.2024.102928_bib0193","doi-asserted-by":"crossref","first-page":"19173","DOI":"10.1074\/jbc.M110.102582","article-title":"A Novel native store-operated calcium channel encoded by Orai3","volume":"285","author":"Motiani","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ceca.2024.102928_bib0194","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1096\/fj.12-213801","article-title":"Orai3 is an estrogen receptor \u03b1-regulated Ca 2+ channel that promotes tumorigenesis","volume":"27","author":"Motiani","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.ceca.2024.102928_bib0277","doi-asserted-by":"crossref","first-page":"14714","DOI":"10.1038\/ncomms14714","article-title":"ORAI2 modulates store-operated calcium entry and T cell-mediated immunity","volume":"8","author":"Vaeth","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ceca.2024.102928_bib0014","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1016\/j.febslet.2014.06.054","article-title":"Atomic force microscopy (AFM) imaging suggests that stromal interaction molecule 1 (STIM1) binds to Orai1 with sixfold symmetry","volume":"588","author":"Balasuriya","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ceca.2024.102928_bib0101","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1038\/s41467-018-06816-8","article-title":"Calcium sensing by the STIM1 ER-luminal domain","volume":"9","author":"Gudlur","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ceca.2024.102928_bib0147","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.205583","article-title":"Molecular anatomy of the early events in STIM1 activation; oligomerization or conformational change?","author":"Korzeniowski","year":"2017","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0164","doi-asserted-by":"crossref","first-page":"9301","DOI":"10.1073\/pnas.0702866104","article-title":"Live-cell imaging reveals sequential oligomerization and local plasma membrane targeting of stromal interaction molecule 1 after Ca 2+ store depletion","volume":"104","author":"Liou","year":"2007","journal-title":"Proc. Natl. Acad. Sci"},{"key":"10.1016\/j.ceca.2024.102928_bib0170","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature07065","article-title":"Oligomerization of STIM1 couples ER calcium depletion to CRAC channel activation","volume":"454","author":"Luik","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ceca.2024.102928_bib0171","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.1038\/ncomms8826","article-title":"Inside-out Ca2+ signalling prompted by STIM1 conformational switch","volume":"6","author":"Ma","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ceca.2024.102928_bib0299","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1073\/pnas.1118947109","article-title":"Structural and mechanistic insights into the activation of Stromal interaction molecule 1 (STIM1)","volume":"109","author":"Yang","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0315","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nsmb.2625","article-title":"Initial activation of STIM1, the regulator of store-operated calcium entry","volume":"20","author":"Zhou","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ceca.2024.102928_bib0131","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1073\/pnas.0806499105","article-title":"Functional stoichiometry of the unitary calcium-release-activated calcium channel","volume":"105","author":"Ji","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0175","doi-asserted-by":"crossref","first-page":"41135","DOI":"10.1074\/jbc.M110.177881","article-title":"Resting state orai1 diffuses as homotetramer in the plasma membrane of live mammalian cells","volume":"285","author":"Madl","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ceca.2024.102928_bib0188","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1113\/jphysiol.2007.146258","article-title":"Both Orai1 and Orai3 are essential components of the arachidonate-regulated Ca 2+ -selective (ARC) channels","volume":"586","author":"Mignen","year":"2008","journal-title":"J. Physiol."},{"key":"10.1016\/j.ceca.2024.102928_bib0218","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature07338","article-title":"The CRAC channel consists of a tetramer formed by Stim-induced dimerization of Orai dimers","volume":"456","author":"Penna","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ceca.2024.102928_bib0116","first-page":"1308","article-title":"Crystal structure of the calcium release-activated calcium channel Orai","volume":"338","author":"Hou","year":"2012","journal-title":"Science (1979)"},{"key":"10.1016\/j.ceca.2024.102928_bib0115","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36758","article-title":"Structures reveal opening of the store-operated calcium channel Orai","volume":"7","author":"Hou","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.ceca.2024.102928_bib0301","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.bpj.2016.09.020","article-title":"Functional analysis of orai1 concatemers supports a hexameric stoichiometry for the CRAC channel","volume":"111","author":"Yen","year":"2016","journal-title":"Biophys. J."},{"key":"10.1016\/j.ceca.2024.102928_bib0114","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1113\/jphysiol.1993.sp019681","article-title":"Calcium release-activated calcium current in rat mast cells","volume":"465","author":"Hoth","year":"1993","journal-title":"J. Physiol."},{"key":"10.1016\/j.ceca.2024.102928_bib0185","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1113\/jphysiol.2012.233098","article-title":"Permeation, selectivity and gating in store-operated CRAC channels","volume":"590","author":"McNally","year":"2012","journal-title":"J. Physiol."},{"key":"10.1016\/j.ceca.2024.102928_bib0302","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature05108","article-title":"Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai","volume":"443","author":"Yeromin","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ceca.2024.102928_bib0049","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1476-5381.1994.tb17072.x","article-title":"Inhibition by SK&F 96365 of Ca2+ current, IL-2 production and activation in T lymphocytes","volume":"113","author":"Chung","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0087","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF00374562","article-title":"Non-specific effects of calcium entry antagonists in mast cells. Pflgers Arch","volume":"428","author":"Franzius","year":"1994","journal-title":"Eur. J. Physiol."},{"key":"10.1016\/j.ceca.2024.102928_bib0172","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1126\/science.287.5458.1647","article-title":"Requirement of the inositol trisphosphate receptor for activation of store-operated ca 2+ channels","volume":"287","author":"Ma","year":"2000","journal-title":"Science (80-.)"},{"key":"10.1016\/j.ceca.2024.102928_bib0173","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1074\/jbc.M107755200","article-title":"Modification of store-operated channel coupling and inositol trisphosphate receptor function by 2-aminoethoxydiphenyl borate in DT40 lymphocytes","volume":"277","author":"Ma","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ceca.2024.102928_bib0224","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1469-7793.2001.t01-1-00003.x","article-title":"Potentiation and inhibition of Ca 2+ release-activated Ca 2+ channels by 2-aminoethyldiphenyl borate (2-APB) occurs independently of IP 3 receptors","volume":"536","author":"Prakriya","year":"2001","journal-title":"J. Physiol."},{"key":"10.1016\/j.ceca.2024.102928_bib0098","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/bj3540285","article-title":"Evidence that 2-aminoethyl diphenylborate is a novel inhibitor of store-operated Ca2+ channels in liver cells, and acts through a mechanism which does not involve inositol trisphosphate receptors","volume":"354","author":"Gregory","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.ceca.2024.102928_bib0127","first-page":"429","article-title":"2-Aminoethoxydiphenyl borate (2-APB) inhibits capacitative calcium entry independently of the function of inositol 1,4,5-trisphosphate receptors","volume":"7","author":"Iwasaki","year":"2001","journal-title":"Receptors Channels"},{"key":"10.1016\/j.ceca.2024.102928_bib0181","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/oxfordjournals.jbchem.a021780","article-title":"2APB, 2-Aminoethoxydiphenyl borate, a membrane-penetrable modulator of ins(1,4,5)P3-induced Ca2+ release","volume":"122","author":"Maruyama","year":"1997","journal-title":"J. Biochem."},{"key":"10.1016\/j.ceca.2024.102928_bib0261","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1093\/emboj\/16.11.3078","article-title":"Genetic evidence for involvement of type 1,type 2and type 3inositol 1,4,5-trisphosphate receptors in signal transduction through the B-cell antigen receptor","volume":"16","author":"Sugawara","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.ceca.2024.102928_bib0097","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceca.2009.10.004","article-title":"Two novel 2-aminoethyl diphenylborinate (2-APB) analogues differentially activate and inhibit store-operated Ca2+ entry via STIM proteins","volume":"47","author":"Goto","year":"2010","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ceca.2024.102928_bib0046","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0008-8749(03)00005-4","article-title":"TH1 and TH2 cytokine inhibition by 3,5-bis(trifluoromethyl)pyrazoles, a novel class of immunomodulators","volume":"220","author":"Chen","year":"2002","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ceca.2024.102928_bib0073","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1021\/jm990615a","article-title":"3,5-Bis(trifluoromethyl)pyrazoles: a Novel Class of NFAT Transcription Factor Regulator","volume":"43","author":"Djuric","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ceca.2024.102928_bib0271","doi-asserted-by":"crossref","first-page":"48118","DOI":"10.1074\/jbc.M107919200","article-title":"Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds","volume":"276","author":"Trevillyan","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ceca.2024.102928_bib0125","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.4049\/jimmunol.170.9.4441","article-title":"A Pyrazole derivative, YM-58483, potently inhibits store-operated sustained Ca2+ Influx and IL-2 Production in T Lymphocytes","volume":"170","author":"Ishikawa","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.ceca.2024.102928_bib0245","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1111\/j.1476-5381.2012.02126.x","article-title":"Novel pyrazole compounds for pharmacological discrimination between receptor-operated and store-operated Ca 2+ entry pathways","volume":"167","author":"Schleifer","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0143","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ejphar.2016.08.030","article-title":"Differential modulation of TWIK-related K+ channel (TREK) and TWIK-related acid-sensitive K+ channel 2 (TASK2) activity by pyrazole compounds","volume":"791","author":"Kim","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.01.070","article-title":"CRACM\/Orai ion channel expression and function in human lung mast cells","volume":"129","author":"Ashmole","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ceca.2024.102928_bib0061","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ceca.2012.11.005","article-title":"The action of selective CRAC channel blockers is affected by the Orai pore geometry","volume":"53","author":"Derler","year":"2013","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ceca.2024.102928_bib0230","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2013.02.022","article-title":"Characterization of selective calcium-release activated calcium channel blockers in mast cells and T-cells from human, rat, mouse and guinea-pig preparations","volume":"704","author":"Rice","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0313","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/aps.2017.117","article-title":"Main active constituent identification in Guanxinjing capsule, a traditional Chinese medicine, for the treatment of coronary heart disease complicated with depression","volume":"39","author":"Zhang","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ceca.2024.102928_bib0144","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4049\/jimmunol.1302586","article-title":"Calcium signaling via orai1 is essential for induction of the nuclear orphan receptor pathway to drive Th17 differentiation","volume":"192","author":"Kim","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.ceca.2024.102928_bib0066","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.4049\/jimmunol.0802887","article-title":"Targeting Gut T Cell Ca2+ Release-Activated Ca2+ Channels Inhibits T Cell Cytokine Production and T-Box Transcription Factor T-Bet in Inflammatory Bowel Disease","volume":"183","author":"Di Sabatino","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ceca.2024.102928_bib0202","doi-asserted-by":"crossref","first-page":"31348","DOI":"10.1074\/jbc.M804942200","article-title":"Sustained Activation of the tyrosine kinase Syk by antigen in mast cells requires local Ca2+ influx through Ca2+ release-activated Ca2+ channels","volume":"283","author":"Ng","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ceca.2024.102928_bib0225","unstructured":"PRCL Research Inc., n.d. A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis [WWW Document]. URL https:\/\/clinicaltrials.gov\/study\/NCT03614078?term=PRCL-02&rank=2."},{"key":"10.1016\/j.ceca.2024.102928_bib0044","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molimm.2012.12.011","article-title":"Characterization of a novel CRAC inhibitor that potently blocks human T cell activation and effector functions","volume":"54","author":"Chen","year":"2013","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ceca.2024.102928_bib0257","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ceca.2018.07.005","article-title":"CRAC channels as targets for drug discovery and development","volume":"74","author":"Stauderman","year":"2018","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ceca.2024.102928_bib0281","unstructured":"VELICELEBI, G., STAUDERMAN, K., WHITTEN, J., PEI, Y., CAO, J., WANG, Z., ROGERS, E., DYCK, B., GREY, J., n.d. US7906553B2 Substituted thiophene modulators of intracellular calcium.<\/bib>."},{"key":"10.1016\/j.ceca.2024.102928_bib0291","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.04.015","article-title":"Inhibitors of ORAI1 prevent cytosolic calcium-associated injury of human pancreatic acinar cells and acute pancreatitis in 3 mouse models","volume":"149","author":"Wen","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ceca.2024.102928_bib0263","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejphar.2015.12.047","article-title":"Pharmacodynamic evaluation of RP3128, a novel and potent CRAC channel inhibitor in guinea pig models of allergic asthma","volume":"772","author":"Sutovska","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0275","series-title":"Safety and Efficacy Study of RP4010, in Patients with Relapsed or Refractory Lymphomas [WWW Document]","year":"2019"},{"key":"10.1016\/j.ceca.2024.102928_bib0276","series-title":"Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals [WWW Document]","year":"2019"},{"key":"10.1016\/j.ceca.2024.102928_bib0278","unstructured":"Vakkalanka, S., Merikapudi, G., Babu, G., Routhu, K., Veeraraghavan, S., Viswanadha, S., n.d. Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders [WWW Document]. URL https:\/\/www.ers-education.org\/lr\/show-details\/?idP=127076."},{"key":"10.1016\/j.ceca.2024.102928_bib0191","doi-asserted-by":"crossref","DOI":"10.1016\/j.conb.2022.01.005","article-title":"Store-operated Ca2+ entry regulates neuronal gene expression and function","volume":"73","author":"Mitra","year":"2022","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.ceca.2024.102928_bib0137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010435","article-title":"A STIM dependent dopamine-neuropeptide axis maintains the larval drive to feed and grow in Drosophila","volume":"19","author":"Kasturacharya","year":"2023","journal-title":"PLoS. Genet."},{"key":"10.1016\/j.ceca.2024.102928_bib0216","doi-asserted-by":"crossref","first-page":"13784","DOI":"10.1523\/JNEUROSCI.1680-15.2015","article-title":"Store-operated calcium entry through orai is required for transcriptional maturation of the flight circuit in drosophila","volume":"35","author":"Pathak","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0096","doi-asserted-by":"crossref","first-page":"42993","DOI":"10.1038\/srep42993","article-title":"CMT-linked loss-of-function mutations in GDAP1 impair store-operated Ca2+ entry-stimulated respiration","volume":"7","author":"Gonz\u00e1lez-S\u00e1nchez","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ceca.2024.102928_bib0177","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108464","article-title":"Orai1 channels are essential for amplification of glutamate-evoked Ca2+ signals in dendritic spines to regulate working and associative memory","volume":"33","author":"Maneshi","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ceca.2024.102928_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2021.02.023","article-title":"Presynaptic store-operated Ca2+ entry drives excitatory spontaneous neurotransmission and augments endoplasmic reticulum stress","volume":"109","author":"Chanaday","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.ceca.2024.102928_bib0064","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1523\/JNEUROSCI.2401-20.2021","article-title":"Purkinje Neurons with Loss of STIM1 Exhibit Age-Dependent Changes in Gene Expression and Synaptic Components","volume":"41","author":"Dhanya","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0105","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.neuron.2014.03.027","article-title":"STIM1 controls neuronal Ca2+ Signaling, mGluR1-dependent synaptic transmission, and cerebellar motor behavior","volume":"82","author":"Hartmann","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.ceca.2024.102928_bib0237","doi-asserted-by":"crossref","first-page":"8876","DOI":"10.1523\/JNEUROSCI.3973-16.2017","article-title":"STIM1 Regulates somatic Ca 2+ signals and intrinsic firing properties of cerebellar purkinje neurons","volume":"37","author":"Ryu","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0032","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/s41467-020-16074-2","article-title":"Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer's disease","volume":"11","author":"Calvo-Rodriguez","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ceca.2024.102928_bib0222","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13024-015-0034-7","article-title":"STIM2 protects hippocampal mushroom spines from amyloid synaptotoxicity","volume":"10","author":"Popugaeva","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ceca.2024.102928_bib0214","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00109-018-1677-y","article-title":"STIM1 deficiency is linked to Alzheimer's disease and triggers cell death in SH-SY5Y cells by upregulation of L-type voltage-operated Ca2+ entry","volume":"96","author":"Pascual-Caro","year":"2018","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0047","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neuroscience.2019.04.043","article-title":"Antagonist of neuronal store-operated calcium entry exerts beneficial effects in neurons expressing PSEN1\u0394E9 mutant linked to familial Alzheimer disease","volume":"410","author":"Chernyuk","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.ceca.2024.102928_bib0176","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3390\/ijms21030842","article-title":"Transgenic mice overexpressing human STIM2 and ORAI1 in neurons exhibit changes in behavior and calcium homeostasis but show no signs of neurodegeneration","volume":"21","author":"Majewski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0077","first-page":"7591","article-title":"Hypoxia induces HT-22 neuronal cell death via Orai1\/CDK5 pathway-mediated Tau hyperphosphorylation","volume":"11","author":"Fang","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.ceca.2024.102928_bib0192","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1523\/JNEUROSCI.4069-15.2016","article-title":"Store-operated calcium entry in m\u00fcller glia is controlled by synergistic activation of TRPC and orai channels","volume":"36","author":"Moln\u00e1r","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0021","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.bbrc.2004.08.035","article-title":"Deranged neuronal calcium signaling and Huntington disease","volume":"322","author":"Bezprozvanny","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ceca.2024.102928_bib0284","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2015.00337","article-title":"Both Orai1 and TRPC1 are involved in excessive store-operated calcium entry in striatal neurons expressing mutant huntingtin exon 1","volume":"6","author":"Vigont","year":"2015","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ceca.2024.102928_bib0293","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1523\/JNEUROSCI.1038-15.2016","article-title":"Enhanced store-operated calcium entry leads to striatal synaptic loss in a huntington's disease mouse model","volume":"36","author":"Wu","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0294","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.chembiol.2011.04.012","article-title":"Neuronal store-operated calcium entry pathway as a novel therapeutic target for huntington's disease treatment","volume":"18","author":"Wu","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ceca.2024.102928_bib0057","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.bbrc.2016.08.106","article-title":"Tetrahydrocarbazoles decrease elevated SOCE in medium spiny neurons from transgenic YAC128 mice, a model of Huntington's disease","volume":"483","author":"Czeredys","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ceca.2024.102928_bib0006","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/practneurol-2014-000849","article-title":"Parkinson's disease: chameleons and mimics","volume":"15","author":"Ali","year":"2015","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.ceca.2024.102928_bib0160","doi-asserted-by":"crossref","first-page":"e83638","DOI":"10.1371\/journal.pone.0083638","article-title":"Inhibition of store-operated calcium entry attenuates MPP+-Induced oxidative stress via preservation of mitochondrial function in pc12 cells: involvement of homer1a","volume":"8","author":"Li","year":"2013","journal-title":"PLoS. One"},{"key":"10.1016\/j.ceca.2024.102928_bib0314","doi-asserted-by":"crossref","first-page":"10332","DOI":"10.1038\/ncomms10332","article-title":"Impairment of PARK14-dependent Ca2+ signalling is a novel determinant of Parkinson's disease","volume":"7","author":"Zhou","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ceca.2024.102928_bib0139","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2015.00448","article-title":"ALS patient stem cells for unveiling disease signatures of motoneuron susceptibility: perspectives on the deadly mitochondria, ER stress and calcium triad","volume":"9","author":"Kaus","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0065","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nn1885","article-title":"Non\u2013cell autonomous effect of glia on motor neurons in an embryonic stem cell\u2013based ALS model","volume":"10","author":"Di Giorgio","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0200","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nn1876","article-title":"Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons","volume":"10","author":"Nagai","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0107","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1083\/jcb.201004152","article-title":"S-glutathionylation activates STIM1 and alters mitochondrial homeostasis","volume":"190","author":"Hawkins","year":"2010","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ceca.2024.102928_bib0140","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1523\/JNEUROSCI.2689-13.2014","article-title":"Abnormal intracellular calcium signaling and SNARE-dependent exocytosis contributes to SOD1G93A astrocyte-mediated toxicity in amyotrophic lateral sclerosis","volume":"34","author":"Kawamata","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0203","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.3390\/ijms20205151","article-title":"ALS-associated SOD1(G93A) decreases SERCA pump levels and increases store-operated Ca2+ entry in primary spinal cord astrocytes from a transgenic mouse model","volume":"20","author":"Norante","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0138","doi-asserted-by":"crossref","first-page":"573","DOI":"10.4049\/jimmunol.1501406","article-title":"Selective ORAI1 inhibition ameliorates autoimmune central nervous system inflammation by suppressing effector but not regulatory T cell function","volume":"196","author":"Kaufmann","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.ceca.2024.102928_bib0153","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202205913","article-title":"Orai1 is an entotic Ca 2+ channel for non-apoptotic cell death, entosis in cancer development","volume":"10","author":"Lee","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0254","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adf9535","article-title":"The Ca 2+ channel ORAI1 is a regulator of oral cancer growth and nociceptive pain","volume":"16","author":"Son","year":"2023","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ceca.2024.102928_bib0080","doi-asserted-by":"crossref","first-page":"e62345","DOI":"10.1371\/journal.pone.0062345","article-title":"Selective Activation of KCa3.1 and CRAC Channels by P2Y2 Receptors Promotes Ca2+ Signaling, Store Refilling and Migration of Rat Microglial Cells","volume":"8","author":"Ferreira","year":"2013","journal-title":"PLoS. One"},{"key":"10.1016\/j.ceca.2024.102928_bib0109","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cellsig.2014.11.003","article-title":"Regulation of phagocytosis and cytokine secretion by store-operated calcium entry in primary isolated murine microglia","volume":"27","author":"Heo","year":"2015","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ceca.2024.102928_bib0120","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/j.bbamcr.2013.06.022","article-title":"Ca 2+ spiking activity caused by the activation of store-operated Ca 2+ channels mediates TNF-\u03b1 release from microglial cells under chronic purinergic stimulation","volume":"1833","author":"Ikeda","year":"2013","journal-title":"Biochim. Biophys. Acta - Mol. Cell Res."},{"key":"10.1016\/j.ceca.2024.102928_bib0121","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bbabio.2013.02.003","article-title":"Two types of fucoxanthin-chlorophyll-binding proteins I tightly bound to the photosystem I core complex in marine centric diatoms","volume":"1827","author":"Ikeda","year":"2013","journal-title":"Biochim. Biophys. Acta - Bioenerg."},{"key":"10.1016\/j.ceca.2024.102928_bib0286","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2015.00492","article-title":"Quetiapine Inhibits Microglial Activation by Neutralizing Abnormal STIM1-Mediated Intercellular Calcium Homeostasis and Promotes Myelin Repair in a Cuprizone-Induced Mouse Model of Demyelination","volume":"9","author":"Wang","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0067","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","article-title":"The P2\u00d77 Receptor in Infection and Inflammation","volume":"47","author":"Di Virgilio","year":"2017","journal-title":"Immunity."},{"key":"10.1016\/j.ceca.2024.102928_bib0204","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev.pharmtox.40.1.563","article-title":"Pharmacology of Cloned P2X Receptors","volume":"40","author":"North","year":"2000","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ceca.2024.102928_bib0069","doi-asserted-by":"crossref","unstructured":"Di Virgilio, F., Jiang, L.H., Roger, S., Falzoni, S., Sarti, A.C., Vultaggio-Poma, V., Chiozzi, P., Adinolfi, E., 2019. Structure, function and techniques of investigation of the P2\u00d77 receptor (P2\u00d77R) in mammalian cells. pp. 115\u2013150. https:\/\/doi.org\/10.1016\/bs.mie.2019.07.043.","DOI":"10.1016\/bs.mie.2019.07.043"},{"key":"10.1016\/j.ceca.2024.102928_bib0136","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.22153","article-title":"Structural basis for subtype-specific inhibition of the P2\u00d77 receptor","volume":"5","author":"Karasawa","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.ceca.2024.102928_bib0243","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fphar.2018.00052","article-title":"The P2\u00d77 Receptor in inflammatory diseases: angel or demon?","volume":"9","author":"Savio","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0285","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1469-7793.1999.0335m.x","article-title":"Kinetics of cell lysis, dye uptake and permeability changes in cells expressing the rat P2\u00d77 receptor","volume":"519","author":"Virginio","year":"1999","journal-title":"J. Physiol."},{"key":"10.1016\/j.ceca.2024.102928_bib0059","doi-asserted-by":"crossref","unstructured":"De Marchi, E., Orioli, E., Dal Ben, D., Adinolfi, E., 2016. P2\u00d77 Receptor as a Therapeutic Target. pp. 39\u201379. https:\/\/doi.org\/10.1016\/bs.apcsb.2015.11.004.","DOI":"10.1016\/bs.apcsb.2015.11.004"},{"key":"10.1016\/j.ceca.2024.102928_bib0068","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00039","article-title":"Non-nucleotide Agonists Triggering P2\u00d77 Receptor Activation and Pore Formation","volume":"9","author":"Di Virgilio","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0014-2999(99)00350-7","article-title":"Pharmacological characterization of recombinant human and rat P2X receptor subtypes","volume":"376","author":"Bianchi","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0309","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115234","article-title":"From lead to clinic: a review of the structural design of P2\u00d77R antagonists","volume":"251","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ceca.2024.102928_bib0236","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3390\/cancers14051116","article-title":"The role of purinergic P2\u00d77 receptor in inflammation and cancer: novel molecular insights and clinical applications","volume":"14","author":"Rotondo","year":"2022","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ceca.2024.102928_bib0229","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1177\/0269881120914206","article-title":"Characterisation of the pharmacodynamic effects of the P2\u00d77 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial","volume":"34","author":"Recourt","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0022","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41386-018-0141-6","article-title":"Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2\u00d77 ion channels in animal models of neuroinflammation and anhedonia","volume":"43","author":"Bhattacharya","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ceca.2024.102928_bib0268","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2967\/jnumed.116.181354","article-title":"Characterization of 11 C-GSK1482160 for Targeting the P2\u00d77 Receptor as a Biomarker for Neuroinflammation","volume":"58","author":"Territo","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2125.2012.04320.x","article-title":"Pharmacokinetic and pharmacodynamic profiling of a P2\u00d77 receptor allosteric modulator GSK1482160 in healthy human subjects","volume":"75","author":"Ali","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0260","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3899\/jrheum.110874","article-title":"Efficacy and safety of CE-224,535, an antagonist of P2\u00d77 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate","volume":"39","author":"Stock","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ceca.2024.102928_bib0142","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1136\/annrheumdis-2011-143578","article-title":"Clinical evaluation of the efficacy of the P2\u00d77 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine","volume":"71","author":"Keystone","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ceca.2024.102928_bib0075","article-title":"Safety and efficacy of an oral inhibitor of the purinergic receptor P2\u00d77 in adult patients with moderately to severely active crohn\u02bcs disease","volume":"1","author":"Eser","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ceca.2024.102928_bib0003","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bcp.2017.12.021","article-title":"The P2\u00d77 receptor: a main player in inflammation","volume":"151","author":"Adinolfi","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0004","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14728222.2023.2258281","article-title":"The neuroinflammatory astrocytic P2\u00d77 receptor: alzheimer's disease, ischemic brain injury, and epileptic state","volume":"27","author":"Ahn","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ceca.2024.102928_bib0033","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/med.21710","article-title":"The purinergic P2\u00d77 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases","volume":"40","author":"Calzaferri","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ceca.2024.102928_bib0122","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.3390\/ijms21175996","article-title":"P2\u00d77 receptors amplify CNS damage in neurodegenerative diseases","volume":"21","author":"Illes","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0255","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tips.2014.08.002","article-title":"P2\u00d77 receptor: an emerging target in central nervous system diseases","volume":"35","author":"Sperlagh","year":"2014","journal-title":"Trends. Pharmacol. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0117","article-title":"P2\u00d77 Receptor: an emerging target in Alzheimer's disease","author":"Huang","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ceca.2024.102928_bib0017","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bbi.2023.09.011","article-title":"P2\u00d77R influences tau aggregate burden in human tauopathies and shows distinct signalling in microglia and astrocytes","volume":"114","author":"Beltran-Lobo","year":"2023","journal-title":"Brain. Behav. Immun."},{"key":"10.1016\/j.ceca.2024.102928_bib0239","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/humu.23218","article-title":"Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis","volume":"38","author":"Sadovnick","year":"2017","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ceca.2024.102928_bib0070","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1096\/fj.08-122275","article-title":"Altered P2\u00d77-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration","volume":"23","author":"D\u00edaz-Hern\u00e1ndez","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.ceca.2024.102928_bib0312","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2174\/1570159X20666220302152400","article-title":"A possible causal involvement of neuroinflammatory, purinergic P2\u00d77 receptors in psychiatric disorders","volume":"20","author":"Zhang","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0010","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.017038","article-title":"Spinal cord pathology is ameliorated by P2\u00d77 antagonism in SOD1-G93A mouse model of amyotrophic lateral sclerosis","author":"Apolloni","year":"2014","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ceca.2024.102928_bib0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuroscience.2014.08.036","article-title":"Brilliant Blue G improves cognition in an animal model of Alzheimer's disease and inhibits amyloid-\u03b2-induced loss of filopodia and dendrite spines in hippocampal neurons","volume":"279","author":"Chen","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.ceca.2024.102928_bib0036","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neuropharm.2014.01.045","article-title":"The P2\u00d77 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis","volume":"81","author":"Carmo","year":"2014","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.ceca.2024.102928_bib0148","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1007\/s11064-017-2383-9","article-title":"Purinergic Antagonism prevents mitochondrial dysfunction and behavioral deficits associated with dopaminergic toxicity induced by 6-OHDA in rats","volume":"42","author":"Kumar","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ceca.2024.102928_bib0207","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2019.00476","article-title":"P2Y6 and P2\u00d77 Receptor antagonism exerts neuroprotective\/neuroregenerative effects in an animal model of Parkinson's disease","volume":"13","author":"Oliveira-Giacomelli","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0063","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.molmed.2018.07.005","article-title":"P2\u00d77 Receptor: a Potential Therapeutic Target for Depression?","volume":"24","author":"Deussing","year":"2018","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0123","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jphs.2022.04.003","article-title":"Overview for the study of P2 receptors: from P2 receptor history to neuropathic pain studies","volume":"149","author":"Inoue","year":"2022","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0174","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2020.580068","article-title":"P2\u00d74R overexpression upregulates interleukin-6 and exacerbates 6-OHDA-induced dopaminergic degeneration in a rat model of PD","volume":"12","author":"Ma","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0037","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cne.21527","article-title":"Strong P2\u00d74 purinergic receptor-like immunoreactivity is selectively associated with degenerating neurons in transgenic rodent models of amyotrophic lateral sclerosis","volume":"506","author":"Casanovas","year":"2008","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.ceca.2024.102928_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11302-018-9633-4","article-title":"Purinergic implication in amyotrophic lateral sclerosis-from pathological mechanisms to therapeutic perspectives","volume":"15","author":"Cieslak","year":"2019","journal-title":"Purinergic. Signal."},{"key":"10.1016\/j.ceca.2024.102928_bib0099","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1096\/fj.12-215368","article-title":"A rare functional haplotype of the P2RX4 and P2RX7 genes leads to loss of innate phagocytosis and confers increased risk of age-related macular degeneration","volume":"27","author":"Gu","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.ceca.2024.102928_bib0238","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/NEN.0b013e318297fd10","article-title":"Immunodetection of disease-associated conformers of mutant cu\/zn superoxide dismutase 1 selectively expressed in degenerating neurons in amyotrophic lateral sclerosis","volume":"72","author":"Sabado","year":"2013","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ceca.2024.102928_bib0264","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.bj.2017.06.010","article-title":"P2\u00d74: a fast and sensitive purinergic receptor","volume":"40","author":"Suurv\u00e4li","year":"2017","journal-title":"Biomed. J."},{"key":"10.1016\/j.ceca.2024.102928_bib0304","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.nbd.2003.10.014","article-title":"Enhanced expression of the P2\u00d74 receptor in Duchenne muscular dystrophy correlates with macrophage invasion","volume":"15","author":"Yeung","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ceca.2024.102928_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.814999","article-title":"Microglial Activation Modulated by P2\u00d74R in Ischemia and Repercussions in Alzheimer's Disease","volume":"13","author":"Castillo","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ceca.2024.102928_bib0296","doi-asserted-by":"crossref","DOI":"10.1007\/s12264-022-00833-w","article-title":"P2\u00d77\/P2\u00d74 receptors mediate proliferation and migration of retinal microglia in experimental glaucoma in mice","author":"Xu","year":"2022","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.ceca.2024.102928_bib0256","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113308","article-title":"Neuroprotective and neuro-rehabilitative effects of acute purinergic receptor P2\u00d74 (P2\u00d74R) blockade after ischemic stroke","volume":"329","author":"Srivastava","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ceca.2024.102928_bib0311","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4103\/1673-5374.313053","article-title":"P2\u00d74 receptor participates in autophagy regulation in Parkinson's disease","volume":"16","author":"Zhang","year":"2021","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.ceca.2024.102928_bib0094","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01330","article-title":"Exploring the role of P2X receptors in alzheimer's disease","volume":"10","author":"Godoy","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0240","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.neuropharm.2017.10.027","article-title":"P2X receptor overexpression induced by soluble oligomers of amyloid beta peptide potentiates synaptic failure and neuronal dyshomeostasis in cellular models of Alzheimer's disease","volume":"128","author":"S\u00e1ez-Orellana","year":"2018","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.ceca.2024.102928_bib0042","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0306-4522(03)00228-8","article-title":"Up-regulation of p2\u00d72, p2\u00d74 receptor and ischemic cell death: prevention by p2 antagonists","volume":"120","author":"Cavaliere","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.ceca.2024.102928_bib0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","article-title":"Drug treatments in Alzheimer's disease","volume":"16","author":"Briggs","year":"2016","journal-title":"Clin. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0054","article-title":"Amantadine in Parkinson's disease","author":"Crosby","year":"2003","journal-title":"Cochrane database Syst. Rev."},{"key":"10.1016\/j.ceca.2024.102928_bib0062","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/mds.29066","article-title":"European Academy of Neurology\/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies","volume":"37","author":"Deuschl","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ceca.2024.102928_bib0155","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/00002512-200522090-00002","article-title":"Alternatives to levodopa in the initial treatment of early Parkinson's disease","volume":"22","author":"Lees","year":"2005","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ceca.2024.102928_bib0198","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3390\/cells11091511","article-title":"Effects of one-day application of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa\/opicapone in parkinson's disease patients","volume":"11","author":"M\u00fcller","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ceca.2024.102928_bib0259","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.parkreldis.2014.08.004","article-title":"Comparison of IPX066 with carbidopa\u2013levodopa plus entacapone in advanced PD patients","volume":"20","author":"Stocchi","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ceca.2024.102928_bib0242","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","article-title":"Parkinson's disease","volume":"363","author":"Samii","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ceca.2024.102928_bib0197","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2217\/nmt-2020-0017","article-title":"Safinamide in the treatment of Parkinson's disease","volume":"10","author":"M\u00fcller","year":"2020","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.ceca.2024.102928_bib0078","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1080\/00207454.2021.1929217","article-title":"Opicapone for the treatment of Parkinson's disease: a review","volume":"133","author":"Feldman","year":"2023","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.ceca.2024.102928_bib0124","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/00002512-200320110-00006","article-title":"Cabergoline, pramipexole and ropinirole used as monotherapy in early parkinsons disease","volume":"20","author":"Inzelberg","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ceca.2024.102928_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18030551","article-title":"Parkinson's Disease: from Pathogenesis to Pharmacogenomics","volume":"18","author":"Cacabelos","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0199","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1212\/WNL.42.2.339","article-title":"Selegiline as initial treatment in de novo parkinsonian patients","volume":"42","author":"Myllyl\u00e4","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.ceca.2024.102928_bib0195","first-page":"173","article-title":"3-O-Methyldopa, l-dopa, and trihexyphenidyl in the treatment of Parkinson's disease","volume":"48","author":"Muenter","year":"1973","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ceca.2024.102928_bib0248","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052400","article-title":"Comprehensive research on past and future therapeutic strategies devoted to treatment of amyotrophic lateral sclerosis","volume":"23","author":"Sever","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ceca.2024.102928_bib0132","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1054006","article-title":"New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0128","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs","volume":"39","author":"Jaiswal","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ceca.2024.102928_bib0189","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0231","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/nmt-2018-0040","article-title":"Deutetrabenazine in the treatment of Huntington's disease","volume":"9","author":"Richard","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.ceca.2024.102928_bib0084","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","article-title":"Treatment of Huntington's disease","volume":"11","author":"Frank","year":"2014","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.ceca.2024.102928_bib0030","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon \u03b2-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.ceca.2024.102928_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0018","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/neurolint13020022","article-title":"Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)","volume":"13","author":"Berger","year":"2021","journal-title":"Neurol. Int."},{"key":"10.1016\/j.ceca.2024.102928_bib0119","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1358\/dot.2021.57.12.3353166","article-title":"Ponesimod to treat multiple sclerosis","volume":"57","author":"Ianniello","year":"2021","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.ceca.2024.102928_bib0129","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/14737175.2023.2268842","article-title":"Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis","volume":"23","author":"Jakimovski","year":"2023","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ceca.2024.102928_bib0151","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002819.pub2","article-title":"Cyclophosphamide for multiple sclerosis","author":"La Mantia","year":"2007","journal-title":"Cochrane database Syst. Rev."},{"key":"10.1016\/j.ceca.2024.102928_bib0150","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/2040622316644481","article-title":"H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes","volume":"7","author":"Kutz","year":"2016","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.ceca.2024.102928_bib0290","doi-asserted-by":"crossref","unstructured":"Weil-Malherbe, H., 1967. The Biochemistry of the Functional Psychoses. pp. 479\u2013553. https:\/\/doi.org\/10.1002\/9780470122747.ch9.","DOI":"10.1002\/9780470122747.ch9"},{"key":"10.1016\/j.ceca.2024.102928_bib0092","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrd2030","article-title":"Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond","volume":"5","author":"Ghofrani","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ceca.2024.102928_bib0011","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ceca.2024.102928_bib0178","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112911","article-title":"Combined drug triads for synergic neuroprotection in retinal degeneration","volume":"149","author":"Maneu","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ceca.2024.102928_bib0024","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2174\/0929867311320130004","article-title":"Polypharmacology in a Single Drug: multitarget Drugs","volume":"20","author":"Bolognesi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ceca.2024.102928_bib0002","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1377\/hlthaff.25.2.420","article-title":"Estimating the cost of new drug development: is it really $802 million?","volume":"25","author":"Adams","year":"2006","journal-title":"Health Aff."},{"key":"10.1016\/j.ceca.2024.102928_bib0072","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.clinthera.2018.04.011","article-title":"Assessing the financial benefits of faster development times: the case of single-source versus multi-vendor outsourced biopharmaceutical manufacturing","volume":"40","author":"DiMasi","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ceca.2024.102928_bib0090","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1056\/NEJMra1602972","article-title":"FDA regulation of prescription drugs","volume":"376","author":"Gassman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0118","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","article-title":"Amantadine: the journey from fighting flu to treating Parkinson disease","volume":"78","author":"Hubsher","year":"2012","journal-title":"Neurology."},{"key":"10.1016\/j.ceca.2024.102928_bib0217","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0019","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","article-title":"Reviews Of Anti-infective Agents: liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis","volume":"43","author":"Bern","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ceca.2024.102928_bib0112","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1463-1326.2010.01304.x","article-title":"Bromocriptine: old drug, new formulation and new indication","volume":"12","author":"Holt","year":"2010","journal-title":"Diabetes, Obes. Metab."},{"key":"10.1016\/j.ceca.2024.102928_bib0130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.canlet.2011.01.012","article-title":"Targeting apoptosis pathways by Celecoxib in cancer","volume":"332","author":"Jendrossek","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ceca.2024.102928_bib0265","first-page":"81","article-title":"Treatment of stress urinary incontinence with duloxetine hydrochloride","volume":"7","author":"Sweeney","year":"2005","journal-title":"Rev. Urol."},{"key":"10.1016\/j.ceca.2024.102928_bib0162","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","article-title":"Galantamine - A novel cholinergic drug with a unique dual mode of action for the treatment of patients with alzheimer's disease","volume":"8","author":"Lilienfeld","year":"2006","journal-title":"CNS. Drug Rev."},{"key":"10.1016\/j.ceca.2024.102928_bib0145","unstructured":"King, R.S., n.d. Gemcitabine. New first-line therapy for pancreatic cancer. Cancer Pract.. 4, 353\u20134."},{"key":"10.1016\/j.ceca.2024.102928_bib0027","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ceca.2024.102928_bib0208","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1067\/mjd.2002.124088","article-title":"A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men","volume":"47","author":"Olsen","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ceca.2024.102928_bib0091","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1161\/01.CIR.0000109694.58299.A0","article-title":"Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent","volume":"109","author":"Gershlick","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ceca.2024.102928_bib0247","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/archneur.55.9.1211","article-title":"Ropinirole for the Treatment of Early Parkinson Disease: a 12-Month Experience","volume":"55","author":"Sethi","year":"1998","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ceca.2024.102928_bib0093","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrd2030","article-title":"Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond","volume":"5","author":"Ghofrani","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ceca.2024.102928_bib0163","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00109-016-1450-z","article-title":"The molecular mechanism of thalidomide analogs in hematologic malignancies","volume":"94","author":"Lindner","year":"2016","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0183","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","article-title":"Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial","volume":"160","author":"McElroy","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ceca.2024.102928_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","article-title":"The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic","volume":"85","author":"Broder","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ceca.2024.102928_bib0158","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1021\/jm500802j","article-title":"Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor","volume":"57","author":"Li","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ceca.2024.102928_bib0008","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.chembiol.2003.09.002","article-title":"The Process of Structure-Based Drug Design","volume":"10","author":"Anderson","year":"2003","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ceca.2024.102928_bib0168","doi-asserted-by":"crossref","DOI":"10.5936\/csbj.201302011","article-title":"Current progress in structure-based rational drug design marks a new mindset in drug discovery","volume":"5","author":"Lounnas","year":"2013","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ceca.2024.102928_bib0179","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev.pharmtox.37.1.71","article-title":"Structure-based drug design:computational advances","volume":"37","author":"Marrone","year":"1997","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ceca.2024.102928_bib0289","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2174\/1568026618666180813152921","article-title":"Structure-based drug design strategies and challenges","volume":"18","author":"Wang","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ceca.2024.102928_bib0186","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: a powerful approach for structure-based drug discovery","volume":"7","author":"Meng","year":"2011","journal-title":"Curr. Comput. Aided-Drug Des."},{"key":"10.1016\/j.ceca.2024.102928_bib0095","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Ganau, S., de Juli\u00e1n-Ortiz, J.V., Gozalbes, R., 2018. Recent Advances in computational approaches for designing potential anti-alzheimer's agents. pp. 25\u201359. https:\/\/doi.org\/10.1007\/978-1-4939-7404-7_2.","DOI":"10.1007\/978-1-4939-7404-7_2"},{"key":"10.1016\/j.ceca.2024.102928_bib0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119264","article-title":"Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis","volume":"10","author":"Mart\u00ednez","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.ceca.2024.102928_bib0221","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3390\/molecules25081971","article-title":"Application of MM-PBSA methods in virtual screening","volume":"25","author":"Poli","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ceca.2024.102928_bib318","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-4939-8955-3_2","article-title":"Performing an in silico repurposing of existing drugs by combining virtual screening and molecular dynamics simulation","volume":"1903","author":"Sohraby","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ceca.2024.102928_bib0060","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/wsbm.147","article-title":"Drug repurposing and adverse event prediction using high-throughput literature analysis","volume":"3","author":"Deftereos","year":"2011","journal-title":"WIREs Syst. Biol. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0056","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.trci.2017.05.002","article-title":"Alzheimer's disease drug development pipeline: 2017. Alzheimer's Dement","volume":"3","author":"Cummings","year":"2017","journal-title":"Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ceca.2024.102928_bib0135","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: a brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0133","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ceca.2024.102928_bib0081","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0297","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nm.4369","article-title":"An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer","volume":"23","author":"Xue","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0306","doi-asserted-by":"crossref","first-page":"32930","DOI":"10.18632\/oncotarget.5405","article-title":"Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo","volume":"6","author":"Yu","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.ceca.2024.102928_bib0055","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science (80-.)."},{"key":"10.1016\/j.ceca.2024.102928_bib0111","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJM199508173330710","article-title":"Time to Hit HIV, Early and Hard","volume":"333","author":"Ho","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0001","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/jama.2015.4562","article-title":"A 4-Drug Combination (Viekira Pak) for Hepatitis C","volume":"313","author":"Abramowicz","year":"2015","journal-title":"JAMa"},{"key":"10.1016\/j.ceca.2024.102928_bib0308","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ceca.2024.102928_bib0241","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41531-023-00589-8","article-title":"Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson's disease - network meta-analysis","volume":"9","author":"Sako","year":"2023","journal-title":"npj Park. Dis"},{"key":"10.1016\/j.ceca.2024.102928_bib0103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212531","article-title":"Combination therapy in the treatment of hypertension","volume":"7","author":"Guerrero-Garc\u00eda","year":"2018","journal-title":"Drugs Context."},{"key":"10.1016\/j.ceca.2024.102928_bib0108","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14656566.2022.2047647","article-title":"Pharmacological treatment options for heart failure with reduced ejection fraction: a 2022 update","volume":"23","author":"Hellenkamp","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ceca.2024.102928_bib0167","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.730257","article-title":"Single-target versus multi-target drugs versus combinations of drugs with multiple targets: preclinical and clinical evidence for the treatment or prevention of epilepsy","volume":"12","author":"L\u00f6scher","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ceca.2024.102928_bib0267","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200320","article-title":"Design of improved antidiabetic drugs: a journey from single to multitarget agents","volume":"17","author":"Tassopoulou","year":"2022","journal-title":"ChemMedChem."},{"key":"10.1016\/j.ceca.2024.102928_bib0233","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-079X.2010.00778.x","article-title":"Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells","volume":"49","author":"Romero","year":"2010","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.ceca.2024.102928_bib0253","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0306-4522(02)00912-0","article-title":"Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia","volume":"118","author":"Sobrado","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.ceca.2024.102928_bib0262","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.drudis.2016.10.008","article-title":"Drug repurposing by integrated literature mining and drug\u2013gene\u2013disease triangulation","volume":"22","author":"Sun","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ceca.2024.102928_bib0146","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ceca.2024.102928_bib0079","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1038\/s41467-020-16952-9","article-title":"Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours","volume":"11","author":"Fernandes Neto","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ceca.2024.102928_bib0041","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.canlet.2019.07.004","article-title":"Low-dose triple drug combination targeting the PI3K\/AKT\/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma","volume":"461","author":"Caumanns","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ceca.2024.102928_bib0212","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107764","article-title":"Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers","volume":"31","author":"Ozkan-Dagliyan","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ceca.2024.102928_bib0303","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.59696","article-title":"Limited inhibition of multiple nodes in a driver network blocks metastasis","volume":"10","author":"Yesilkanal","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.ceca.2024.102928_bib0134","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/dji005","article-title":"CYP2D6 Genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment","volume":"97","author":"Jin","year":"2005","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.ceca.2024.102928_bib0102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4062\/biomolther.2021.102","article-title":"Inhibition of cytochrome p450 enzymes by drugs-molecular basis and practical applications","volume":"30","author":"Guengerich","year":"2022","journal-title":"Biomol. Ther. (Seoul)."},{"key":"10.1016\/j.ceca.2024.102928_bib0292","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1128\/AAC.01124-13","article-title":"Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine","volume":"57","author":"Williamson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ceca.2024.102928_bib0250","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2188","article-title":"The trouble with making combination drugs","volume":"5","author":"Simon","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ceca.2024.102928_bib0141","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00023210-200519020-00006","volume":"19","author":"Keating","year":"2005","journal-title":"Tolcapone. CNS Drugs"},{"key":"10.1016\/j.ceca.2024.102928_bib0273","article-title":"Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease","volume":"109","author":"Truong","year":"2009","journal-title":"Clin. Interv. Aging"}],"container-title":["Cell Calcium"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143416024000861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143416024000861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T10:12:55Z","timestamp":1726049575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143416024000861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":313,"alternative-id":["S0143416024000861"],"URL":"https:\/\/doi.org\/10.1016\/j.ceca.2024.102928","relation":{},"ISSN":["0143-4160"],"issn-type":[{"value":"0143-4160","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting calciumopathy for neuroprotection: focus on calcium channels Cav1, Orai1 and P2X7","name":"articletitle","label":"Article Title"},{"value":"Cell Calcium","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ceca.2024.102928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102928"}}